Anika Therapeutics reported third quarter 2026 revenue of $30.6 million, exceeding analyst consensus, though the core Commercial Channel underperformed specific targets. While the company raised its adjusted EBITDA outlook and total revenue floor, it lowered Commercial Channel guidance due to a slower elective surgery market and received a significant regulatory setback with a "not approvable" letter from the FDA for its Hyalofast PMA application.
Key Highlights
- Total revenue increased 10% year-over-year to $30.6 million, supported by 17% growth in the Commercial Channel and 5% in the OEM Channel.
- Gross margin expanded significantly to 62%, up from 56% in the prior-year period, driven by manufacturing productivity and volume gains despite product mix headwinds.
- Commercial Channel revenue of $14.0 million missed the estimated $14.8 million, leading the company to reduce full-year channel growth guidance to 9%-13% from the previous 12%-18%.
- The FDA notified the company that the Hyalofast PMA application is not approvable based on clinical data, stalling the anticipated U.S. launch strategy.